In Depth 4 Oct 2024
The biggest private biotech investments in September 2024
The companies Candid Therapeutics, ArsenalBio, and eGenesis bagged the biggest private biotech investments in September 2024.
- Latest Posts
Podcast 4 Oct 2024
Targeting telomerase to disrupt cancer
Listen to our conversation with Vlad Vitoc, CEO of MAIA, on the pioneering approach of telomere targeting
Best in Biotech 3 Oct 2024
Six biotechs driving progress in Duchenne muscular dystrophy
In this article, we take a look at six clinical-stage biotechs that are fostering R&D in the Duchenne muscular dystrophy therapeutic space.
News and Trends 3 Oct 2024
Resolution Therapeutics raises $85 million to advance its macrophage therapy
Find out about Resolution Therapeutics’ macrophage therapy, as it just raised $85 million in a series B round.
News and Trends 2 Oct 2024
Niemann-Pick disease: FDA approves first two drugs in the space of a week for rare disorder
Find out all about the first two FDA drug approvals for the rare genetic disorder Niemann-Pick disease type C.
Best in Biotech 1 Oct 2024
Lithuania’s biotech: Six companies to put on your radar
Here are six companies at the forefront of Lithuania’s growing biotech scene, showcasing innovations in protein engineering and gene editing.
ADVERTISEMENT
ADVERTISEMENT
Sublingual delivery: the future for GLP-1 receptor agonists
Discover how GLP-1 receptor agonists, now thriving in obesity treatment, could benefit from a more patient-friendly sublingual delivery method.
News and Trends 30 Sep 2024
The race for a bird flu vaccine: milestones and breakthroughs
The recent uptick in U.S. bird flu cases poses a threat to public health. Biotechs are now developing vaccines to mitigate the outbreak.
News and Trends 27 Sep 2024
Aptadir Therapeutics launches to develop new class of RNA inhibitors against cancer and genetic disorders
Italian startup Aptadir Therapeutics has launched with $1.6 million to bring a new class of drugs to the clinic and a technology to be reckoned with.
Podcast 27 Sep 2024
Harnessing the body’s natural targeted protein degradation system to treat diseases
Listen to our conversation with Andrew Hirsch, CEO at C4 Therapeutics, a leader in the targeted protein degradation field.
In Depth 26 Sep 2024
The radiopharmaceutical revolution: From diagnosis to treatment, oncology and beyond
Delve into the world of radiopharmaceuticals: explore their mechanisms, promising candidates, and the key players driving innovation.
Best in Biotech 26 Sep 2024
Europe’s rising biotech stars: 10 startups to watch in 2024
The European biotech industry is bustling with activity this year. Here’s a list of 10 European biotech companies likely to make a big splash.
ADVERTISEMENT
